Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
- 1 June 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 81 (6) , 1974-1980
- https://doi.org/10.1161/01.cir.81.6.1974
Abstract
Single-chain urokinase plasminogen activator (scu-PA) that had been modified with N-succinimidyl-3-(2-pyridyldithio)propionate was covalently linked by disulfide bonds to the Fab' of a monoclonal antibody specific for the beta-chain of fibrin (antibody 59D8). scu-PA-59D8 Fab' conjugate was separated from free scu-PA and two-chain urokinase coupled to 59D8 Fab' by two-step affinity chromatography. First, the reaction mixture was chromatographed on a column containing Sepharose linked to the peptide that had been used as immunogen for antibody 59D8; scu-PA-59D8 Fab' conjugate and unconjugated 59D8 Fab' were retained but not unconjugated scu-PA. Then, the eluate from the peptide-Sepharose column was chromatographed on a column containing Sepharose linked to benzamidine, which acts as a ligand for two-chain urokinase. The molecular weight of the scu-PA-59D8 Fab' conjugate was approximately 100 kDa when electrophoresed on a nonreducing sodium dodecylsulfate-polyacrylamide gel. Enzymatic assay after purification revealed that more than 97% of the scu-PA present in the conjugate retained the single-chain form. The Fab' portion of the conjugate functioned in a manner indistinguishable from that of native antibody 59D8. In an in vitro assay for lysis of fibrin monomer, the fibrinolytic potency of scu-PA-59D8 Fab' was 33-fold more than that of tissue plasminogen activator (p less than 0.001), 230-fold more than that of unconjugated scu-PA (p less than 0.0001), and 420-fold more than that of urokinase (p less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)This publication has 22 references indexed in Scilit:
- Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarctionThe American Journal of Cardiology, 1988
- Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitroBiochemistry, 1988
- Thrombolysis by a fibrin-specific antibody fab′-urokinase conjugateJournal of Molecular and Cellular Cardiology, 1987
- Antibody-Directed Urokinase: A Specific Fibrinolytic AgentScience, 1985
- Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G 1 FragmentsScience, 1985
- Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.Journal of Clinical Investigation, 1984
- Monoclonal Antibodies to a Synthetic Fibrin-Like Peptide Bind to Human Fibrin But Not FibrinogenScience, 1983
- Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis. EFFECT OF MOLECULAR FORM AND DOSE OF ACTIVATOR, AGE OF THE THROMBUS, AND ROUTE OF ADMINISTRATIONJournal of Clinical Investigation, 1983
- Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolusNature, 1981
- Purification of urokinase by affinity chromatographyBiochimica et Biophysica Acta (BBA) - Enzymology, 1976